{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T01:38:13Z","timestamp":1761183493350,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T00:00:00Z","timestamp":1697846400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100022274","name":"Daiichi Sankyo Europe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022274","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.dmpk.2023.100535","type":"journal-article","created":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T04:54:20Z","timestamp":1697691260000},"page":"100535","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Exposure-response analysis of the efficacy and safety of esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker, in hypertensive patients with or without diabetic kidney disease"],"prefix":"10.1016","volume":"55","author":[{"given":"Kazutaka","family":"Yoshihara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0206-2956","authenticated-orcid":false,"given":"Masato","family":"Fukae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Kastrissios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russell","family":"Wada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takako","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.dmpk.2023.100535_bib1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/nrendo.2009.263","article-title":"Aldosterone and arterial hypertension","volume":"6","author":"Tomaschitz","year":"2010","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"10.1016\/j.dmpk.2023.100535_bib2","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1001\/jama.1974.03230180016005","article-title":"Treatment of low-renin essential hypertension. Comparison of spironolactone and a hydrochlorothiazide-triamterene combination","volume":"227","author":"Douglas","year":"1974","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.dmpk.2023.100535_bib3","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","article-title":"Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension","volume":"15","author":"Weinberger","year":"2002","journal-title":"Am J Hypertens"},{"issue":"3","key":"10.1016\/j.dmpk.2023.100535_bib4","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.semnephrol.2014.04.008","article-title":"Prediction and management of hyperkalemia across the spectrum of chronic kidney disease","volume":"34","author":"Lazich","year":"2014","journal-title":"Semin Nephrol"},{"year":"2021","series-title":"Selara tablets 25 mg\/Selara tablets 50 mg\/Selara tablets 100 mg [package insert]","key":"10.1016\/j.dmpk.2023.100535_bib5"},{"issue":"5","key":"10.1016\/j.dmpk.2023.100535_bib6","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/MNH.0000000000000147","article-title":"Nonsteroidal antagonists of the mineralocorticoid receptor","volume":"24","author":"Kolkhof","year":"2015","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.dmpk.2023.100535_bib7","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ejphar.2015.06.015","article-title":"Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist","volume":"761","author":"Arai","year":"2015","journal-title":"Eur J Pharmacol"},{"issue":"7","key":"10.1016\/j.dmpk.2023.100535_bib8","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/s41371-019-0207-x","article-title":"Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study","volume":"33","author":"Ito","year":"2019","journal-title":"J\u00a0Hum Hypertens"},{"issue":"1","key":"10.1016\/j.dmpk.2023.100535_bib9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.119.13569","article-title":"Double-blind randomized phase 3 study comparing esaxerenone (CS-3150) and eplerenone in patients with essential hypertension (ESAX-HTN study)","volume":"75","author":"Ito","year":"2020","journal-title":"Hypertension"},{"issue":"8","key":"10.1016\/j.dmpk.2023.100535_bib10","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.2215\/CJN.14751218","article-title":"Efficacy and safety of esaxerenone (CS-3150) for the treatment of type 2 diabetes with microalbuminuria: a randomized, double-blind, placebo-controlled, phase II trial","volume":"14","author":"Ito","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"10.1016\/j.dmpk.2023.100535_bib11","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2215\/CJN.06870520","article-title":"Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): phase 3 randomized controlled clinical trial","volume":"15","author":"Ito","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.dmpk.2023.100535_bib12","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/s41440-020-00585-y","article-title":"Antihypertensive effects and safety of esaxerenone in patients with moderate kidney dysfunction","volume":"44","author":"Ito","year":"2021","journal-title":"Hypertens Res"},{"issue":"10","key":"10.1016\/j.dmpk.2023.100535_bib13","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1038\/s41440-019-0270-2","article-title":"Efficacy and safety of dosage-escalation of low-dosage esaxerenone added to a RAS inhibitor in hypertensive patients with type 2 diabetes and albuminuria: a single-arm, open-label study","volume":"42","author":"Itoh","year":"2019","journal-title":"Hypertens Res"},{"year":"2022","series-title":"Minnebro tablets 1.25 mg\/Minnebro tablets 2.5 mg\/Minnebro tablets 5 mg [package insert]","key":"10.1016\/j.dmpk.2023.100535_bib14"},{"issue":"4","key":"10.1016\/j.dmpk.2023.100535_bib15","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/s41440-020-00569-y","article-title":"Management of hyperkalemia during treatment with mineralocorticoid receptor blockers: findings from esaxerenone","volume":"44","author":"Rakugi","year":"2021","journal-title":"Hypertens Res"},{"issue":"10","key":"10.1016\/j.dmpk.2023.100535_bib16","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/psp4.12015","article-title":"Establishing good practices for exposure-response analysis of clinical endpoints in drug development","volume":"4","author":"Overgaard","year":"2015","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.dmpk.2023.100535_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2023.100516","article-title":"Population pharmacokinetics of esaxerenone, a novel non-steroidal mineralocorticoid receptor blocker, in patients with essential hypertension, patients with diabetic nephropathy, and healthy volunteers","volume":"52","author":"Yoshihara","year":"2023","journal-title":"Drug Metabol Pharmacokinet"},{"issue":"7","key":"10.1016\/j.dmpk.2023.100535_bib18","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1111\/bcp.13577","article-title":"Full covariate modelling approach in population pharmacokinetics: understanding the underlying hypothesis tests and implications of multiplicity","volume":"84","author":"Xu","year":"2018","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.dmpk.2023.100535_bib19","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1161\/HYPERTENSIONAHA.116.06602","article-title":"Sex differences in hypertension: recent advances","volume":"68","author":"Gillis","year":"2016","journal-title":"Hypertension"},{"issue":"12","key":"10.1016\/j.dmpk.2023.100535_bib20","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s11906-020-01113-6","article-title":"Female sex, a major risk factor for salt-sensitive hypertension","volume":"22","author":"Faulkner","year":"2020","journal-title":"Curr Hypertens Rep"},{"issue":"5","key":"10.1016\/j.dmpk.2023.100535_bib21","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/ajh.2011.245","article-title":"Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension","volume":"25","author":"Shibata","year":"2012","journal-title":"Am J Hypertens"},{"issue":"3","key":"10.1016\/j.dmpk.2023.100535_bib22","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.tem.2005.02.004","article-title":"Low renin hypertensive states: perspectives, unsolved problems, future research","volume":"16","author":"Gordon","year":"2005","journal-title":"Trends Endocrinol Metabol"},{"issue":"12 Pt 1","key":"10.1016\/j.dmpk.2023.100535_bib23","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.amjhyper.2005.06.010","article-title":"Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone?","volume":"18","author":"Mahmud","year":"2005","journal-title":"Am J Hypertens"},{"issue":"Suppl 3","key":"10.1016\/j.dmpk.2023.100535_bib24","article-title":"Hyperkalemia: pathophysiology, risk factors and consequences","volume":"34","author":"Hunter","year":"2019","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1016\/j.dmpk.2023.100535_bib25","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/cpt.2162","article-title":"The drug titration paradox: correlation of more drug with less effect in clinical data","volume":"110","author":"Schnider","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"16","key":"10.1016\/j.dmpk.2023.100535_bib26","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.108.778811","article-title":"Serum potassium and clinical outcomes in the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS)","volume":"118","author":"Pitt","year":"2008","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.dmpk.2023.100535_bib27","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000024882","article-title":"The safety and efficacy of low-dose mineralocorticoid receptor antagonists in dialysis patients: a meta-analysis","volume":"100","author":"Zhu","year":"2021","journal-title":"Medicine (Baltim)"}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436723000472?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436723000472?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:57:05Z","timestamp":1761163025000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436723000472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":27,"alternative-id":["S1347436723000472"],"URL":"https:\/\/doi.org\/10.1016\/j.dmpk.2023.100535","relation":{},"ISSN":["1347-4367"],"issn-type":[{"type":"print","value":"1347-4367"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exposure-response analysis of the efficacy and safety of esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker, in hypertensive patients with or without diabetic kidney disease","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Pharmacokinetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmpk.2023.100535","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100535"}}